+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A new conjugate vaccine against pneumococcal disease

A new conjugate vaccine against pneumococcal disease

Nurse Practitioner 26(5): 52 55-6 59-62

Streptococcus pneumoniae (pneumococcus) is a major cause of morbidity and mortality, particularly among infants and children. Pneumococcal 7-valent conjugate vaccine (PNCRM7) is the first conjugate vaccine known to prevent most invasive pneumococcal disease in infants and children. PNCRM7, which has a favorable safety profile, provides protection against invasive disease caused by antibiotic-resistant strains of S. pneumoniae, and the vaccine has demonstrated a significant impact on otitis media recurrence. Routine immunization with this vaccine should substantially reduce morbidity and mortality and improve the quality of life for infants, children, and their families.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 045079697

Download citation: RISBibTeXText

PMID: 11383494

Related references

Serum opsonic activity in infants with sickle-cell disease immunized with pneumococcal polysaccharide protein conjugate vaccine. The Pneumococcal Conjugate Vaccine Study Group. Clinical and Diagnostic Laboratory Immunology 7(5): 788-793, 2000

Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine. Pediatric Infectious Disease Journal 33(10): 1065-1076, 2014

Insight Into Resistance Phenotypes of Emergent Non 13-valent Pneumococcal Conjugate Vaccine Type Pneumococci Isolated From Invasive Disease After 13-valent Pneumococcal Conjugate Vaccine Implementation in France. Open Forum Infectious Diseases 3(1): Ofw020, 2016

Indirect cohort analysis of 10-valent pneumococcal conjugate vaccine effectiveness against vaccine-type and vaccine-related invasive pneumococcal disease. Vaccine 33(46): 6145-6148, 2015

Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China. Pediatric Infectious Disease Journal 35(11): E353-E361, 2016

Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). Mmwr. Recommendations and Reports 59(Rr-11): 1-18, 2010

Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clinical Infectious Diseases 37(9): 1155-1164, 2003

Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. International Journal of Infectious Diseases 14(3): E197-E209, 2010

Heptavalent pneumococcal conjugate vaccine primes for antibody response to pure polysaccharide pneumococcal vaccine following treatment for Hodgkins Disease. Pediatric Research 37(4 Part 2): 171A, 1994

Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. Journal of Infectious Diseases 191(7): 1063-1067, 2005

Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. Journal of Infectious Diseases 173(1): 256-258, 1996

Combined schedule of pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine in patients with sickle cell disease. Pediatric Research 41(4 Part 2): 132A, 1997

Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatric Infectious Disease Journal 33(Suppl. 2): S109-S118, 2014

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics 106(5): 965-972, 2000

IgG levels against 13-valent pneumococcal conjugate vaccine serotypes in non pneumococcal conjugate vaccine immunized healthy Japanese and intravenous immunoglobulin preparations. Journal of Infection and ChemoTherapy 20(12): 794-798, 2014